|
Apr 25
|
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS
|
|
Apr 25
|
Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca
|
|
Apr 24
|
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
|
|
Apr 24
|
Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics
|
|
Apr 24
|
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
|
|
Apr 24
|
Can Biogen Keep the Beat Streak Alive This Earnings Season?
|
|
Apr 23
|
AstraZeneca pushes EU to spend more on drugs amid Trump tariffs threat
|
|
Apr 23
|
Drug firm bosses call for price increases in Europe amid tariff uncertainty
|
|
Apr 23
|
Why Tempus AI Stock Is Skyrocketing Today
|
|
Apr 22
|
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
|
|
Apr 22
|
AstraZeneca rejoins leading U.S. drug lobby group after two-year absence
|
|
Apr 22
|
Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial
|
|
Apr 21
|
Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...
|
|
Apr 21
|
AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial
|
|
Apr 21
|
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?
|
|
Apr 21
|
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
|
|
Apr 21
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer
|
|
Feb 15
|
AstraZeneca: IMFINZI improved event-free survival, OS across MIBC
|
|
Feb 15
|
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
|
|
Feb 14
|
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
|